Cytosorbents Regains Minimum Bid Price on Nasdaq, Advances Product Toward FDA Review
What happened
CytoSorbents Corporation regained compliance with the Nasdaq minimum bid price requirement of $1.00 per share on September 23, 2026. This status was achieved after the company's common stock closed at $1.00 per share or greater for 10 consecutive trading sessions ending September 21, 2026. The company is also advancing its DrugSorb-ATR product toward FDA regulatory approval.
From prnewswire.com
Why it matters
The regained compliance removes a major listing overhang for the company on the Nasdaq exchange. Furthermore, the company is actively working toward full compliance with Nasdaq's Capital Market listing requirements regarding the minimum Market Value of Listed Securities before the December 28, 2026 deadline.
From prnewswire.com
Who's involved
- CytosorbentsCompany whose stock listing status was reviewed by Nasdaq.
- NasdaqThe American stock exchange where Cytosorbents is listed.
- FDAThe agency that regulates Cytosorbents' drug submissions.
- Phillip ChanChief Executive Officer of Cytosorbents.
Keep exploring
The entities involved
-
Cytosorbents
company
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
- FDA
Related events
- Black Titan Corp failed to meet the minimum bid price requirement of $1.00 per share on Nasdaq as of September 4, 2026.
- The FDA upheld the De Novo denial for DrugSorb-ATR, a product of CytoSorbents. Phillip Chan serves as the company's CEO.
- OSR Health, Inc.'s share price declined below the minimum bid threshold on Nasdaq on August 19, 2026.
- CLPS Incorporation regained compliance with minimum bid price requirement on September 4, 2026.
- ADC Therapeutics is seeking accelerated approval from the FDA for its Zynlonta therapy.